AVCNF (Avicanna) Pre-Tax Income : $-2.65 Mil (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Avicanna Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Avicanna's pretax income for the three months ended in Dec. 2024 was $0.09 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-2.65 Mil. Avicanna's pretax margin was 2.00%.

During the past 9 years, Avicanna's highest Pretax Margin was -14.17%. The lowest was -13836.90%. And the median was -1372.58%.

Avicanna Pre-Tax Income Historical Data

The historical data trend for Avicanna's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avicanna Pre-Tax Income Chart

Avicanna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Pre-Tax Income

Get a 7-Day Free Trial

-27.36

-13.10

-10.85

-6.52

-2.54

Avicanna Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial															-2.27	-0.75	-1.42	-0.58	0.09

Competitive Comparison of Avicanna's Pre-Tax Income

For the Drug Manufacturers - Specialty & Generic subindustry, Avicanna's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avicanna's Pre-Tax Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avicanna's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Avicanna's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

Avicanna Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Avicanna's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-3.285	+	0.98	+	-0.234	+	0	+	0
	=	-2.54

Avicanna's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-0.857	+	0.964	+	-0.015	+	0	+	0.001
	=	0.09

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.65 Mil.

Avicanna (OTCPK:AVCNF) Pre-Tax Income Explanation

Avicanna's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	0.093	/	4.644
	=	2.00%

During the past 9 years, Avicanna's highest Pretax Margin was -14.17%. The lowest was -13836.90%. And the median was -1372.58%.

Avicanna Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Avicanna's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Avicanna Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (OTCPK:AVCNF) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

0NN:Germany AVCN:Canada

Address

480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2

Website

https://www.avicanna.com

Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.